pharmaphorum| News & views on pharma and biotech’s evolving future

News

Data could move J&J's Talvey earlier in myeloma therapy

Johnson & Johnson's Talvey looks set to move second-line in multiple myeloma treatment, based on the results of the MonumenTAL-3 trial at EHA 2026.

Sales & Marketing

Scissors snipping off half of workforce concept

The hidden risks of biotech layoffs: Why cost-cutting trigge...

Reducing your team without a strategic risk plan actually spikes corporate vulnerability more than it lowers burn rates.

Market Access

Can direct-to-employer models close the GLP-1 obesity care g...

News

NHS study launched to tackle antimicrobial resistance threat

A new study will attempt to improve screening for CPE, one of the fastest-growing drug-resistant bacterial threats facing hospitals in England.

News

AZ's Truqap and Roche assay cleared for PTEN prostate cancer

AstraZeneca has claimed a second approval for AKT inhibitor Truqap, in prostate cancer, that should help achieve its blockbuster hopes for the drug.

Featured Content

Sales & Marketing

The hidden risks of biotech layoffs: Why cost-cutting trigge...

Reducing your team without a strategic risk plan actually spikes corporate vulnerability more than it lowers burn rates.

Spotlight on

ASCO 2026

As the buzz increases in volume and the clock to kick-off counts down, keep an eye on this Spotlight On page for content coming to you from onsite in Chicago. We’ll have features and video content rolling out as the presentations unfold day by day.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/register.png

Digital

Sponsored

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Patients

pharmaphorum podcast Episode 263, Rebecca Guntern - Sandoz

Biosimilars & patient access independent of geographies or s...

Rebecca Guntern, Sandoz' CCO, discusses the ‘golden decade’ for generics and biosimilars as so many blockbuster drugs come off patent.

Patients

ASCO 2026: Quality of life, not just quantity, with Dr Harol...

Dr Harold Keer, chief medical officer at Taiho Oncology, goes in-depth about why his company places such an emphasis on oral formulations.

R&D

Sponsored

From Alzheimer’s disease research to the real-world setting:...

In a new white paper, Lucid Strategy Consulting suggests three key themes for pharma strategists seeking market leadership in the Alzheimer's space.

Newsletters and Deep Dive
digital magazine

Latest News

News

Data could move J&J's Talvey earlier in myeloma therapy

Johnson & Johnson's Talvey looks set to move second-line in multiple myeloma treatment, based on the results of the MonumenTAL-3 trial at EHA 2026.

News

NHS study launched to tackle antimicrobial resistance threat

A new study will attempt to improve screening for CPE, one of the fastest-growing drug-resistant bacterial threats facing hospitals in England.

News

AZ's Truqap and Roche assay cleared for PTEN prostate cancer

AstraZeneca has claimed a second approval for AKT inhibitor Truqap, in prostate cancer, that should help achieve its blockbuster hopes for the drug.

News

Surgical gloves hold a vaccination vial and syringe

UK offers meningitis jab to young people after outbreak

The UK government has responded to calls to broaden vaccinations for meningitis B, offering the jab to "thousands" of young people this summer.

Views & Analysis

Sales & Marketing

The hidden risks of biotech layoffs: Why cost-cutting trigge...

Reducing your team without a strategic risk plan actually spikes corporate vulnerability more than it lowers burn rates.

Patients

Hands holding graphic representation of a kidney on a blue background

The forgotten few: Why the kidney transplant system is faili...

While innovation has reshaped therapeutic areas like oncology, transplant medicine has, by comparison, stood still.

Sales & Marketing

Agile learning focused on driving change: Lessons for Centre...

Less than 30% of digital transformations succeed across industries, while biopharma remains significantly behind (~20% succeed), with only a small minority of companies achieving scaled, en

Oncology

Bridging the cancer drug development gap: AI-driven precisio...

Functional precision oncology gives physicians the data they need to make better decisions about each patient’s care.

Deep Dive

Market Access

Market Access 2026

Market Access

Five dynasties that built modern pharma

Market Access

MFN and TrumpRx: What’s the real impact for the American con...

Market Access

The expanding role of early-phase trials in modern drug deve...

White Papers & Webinar

R&D

Sponsored

From Alzheimer’s disease research to the real-world setting:...

In a new white paper, Lucid Strategy Consulting suggests three key themes for pharma strategists seeking market leadership in the Alzheimer's space.

Digital

Sponsored

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

R&D

From obesity to outcomes abstract visual

Sponsored

The future of cardiometabolic trials: From obesity to outcom...

Gain practical insight into how leading experts are designing the next generation of cardiometabolic trials in an upcoming webinar from hVIVO

R&D

Sponsored

A data-driven guide to small molecule drug discovery and dev...

A new white paper from Excelra takes a closer look at how discovery teams actually experience the small molecule development journey.

Podcasts & Video

Patients

ASCO 2026: Quality of life, not just quantity, with Dr Harol...

Dr Harold Keer, chief medical officer at Taiho Oncology, goes in-depth about why his company places such an emphasis on oral formulations.

Oncology

ASCO 2026: Takeda’s Innovent deal bears fruit, with Teresa B...

Teresa Bitetti and PK Morrow share some of the highlights from Takeda’s data at the show as well as discussing how it fits into their larger strategy.

Patients